July 18, 2018
Hyleukin-7 Selected as a Korea Drug Development Fund (KDDF) Project for Combination Trial with Merck’s KEYTRUDA®
June 1, 2018
NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.
May 2, 2018
NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers